We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 1,090

Keeping Up To Date On CRISPR - July 2016
  • Foley & Lardner LLP
  • USA
  • July 29 2016

CRISPR is a gene editing technique that promises to revolutionize genetic engineering, but already is raising ethical, business, and legal issues


CRISPR Update - July 2016
  • Foley & Lardner LLP
  • USA
  • July 29 2016

This is the first update on CRISPR, following on from our June 24 web conference entitled, "Navigating the CRISPR Patent Landscape and Business


Advancing New Claims Under the Lanham Act
  • Foley & Lardner LLP
  • USA
  • July 28 2016

Implementing unique litigation tactics, on June 15, 2016, Foley & Larder LLP filed a complaint under Section 337 of the Tariff Act at the


The Promise And Pitfalls Of 3D Printing
  • Foley & Lardner LLP
  • USA
  • July 27 2016

3D printing offers great promise for innovation and manufacturing, but this tool has expanded the scope of patented products that can be easily and


Magnum Offers New Path for Challenging AIA Decisions: Burden of Production
  • Foley & Lardner LLP
  • USA
  • July 26 2016

Yesterday, the Court of Appeals for the Federal Circuit (CAFC) held in In re Magnum Oil Tools International (Newman, O’Malley & Chen) that the burden


Can FDA Implement The BPCIA As The CAFC Suggested?
  • Foley & Lardner LLP
  • USA
  • July 21 2016

In Amgen v. Apotex, the Federal Circuit held that under the Biologics Price Competition and Innovation Act (“BPCIA”), “an applicant must provide a


Could the Flying Car Finally Take Off?
  • Foley & Lardner LLP
  • USA
  • July 21 2016

Autonomous vehicles have been hailed as the solution to overcrowded roads and their impact on America's aging infrastructure. However, recent


En Banc CAFC Requires UCC Sale For On Sale Bar
  • Foley & Lardner LLP
  • USA
  • July 19 2016

In an en banc decision issued in The Medicines Company v. Hospira, Inc., the Federal Circuit determined that in order for a commercial transaction to


USPTO Patent Eligibility Guidance In View Of CellzDirect And Sequenom
  • Foley & Lardner LLP
  • USA
  • July 18 2016

On July 14, 2016, the USPTO issued a Memorandum to the Patent Examining Corps on patent eligibility in view of recent court decisions. The July 2016


Janssen Seeks Injunction Against Remicade Biosimilar Based On Cell Culture Patent
  • Foley & Lardner LLP
  • USA
  • July 14 2016

In a complaint filed June 14, 2016, Janssen Biotech Inc. seeks a preliminary injunction that would bar Celltrion and Hospira from selling the